Cinacalcet HCl: A calcimimetic agent for the management of primary and secondary hyperparathyroidism

Expert Opinion on Investigational Drugs

Volumn 12, Issue 8, 2003, Pages 1413-1421

  Franceschini, Nora ^a   Joy, Melanie S ^a   Kshirsagar, Abhijit ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

AMG 073; Calcimimetic; Calcium sensing receptor; Cinacalcet HCl; Primary hyperparathyroidism; Secondary hyperparathyroidism

Indexed keywords

ALUMINUM DERIVATIVE; ASPARAGINASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM DERIVATIVE; CALCIUM ION; CALCIUM SENSING RECEPTOR; CINACALCET; CISPLATIN; DOXORUBICIN; FOSCARNET; FUROSEMIDE; GALLIUM NITRATE; GLUCOCORTICOID; IRON DERIVATIVE; KETOCONAZOLE; MAGNABID; MAGNESIUM DERIVATIVE; MITHRAMYCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PENTAMIDINE; PHENYLALKYLAMINE; PHOSPHATE BINDING AGENT; R 467; R 568; SEVELAMER; SODIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

ABDOMINAL PAIN; ACIDOSIS; ANEMIA; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CLINICAL TRIAL; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; DYSPNEA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; NAUSEA AND VOMITING; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PRIMARY HYPERPARATHYROIDISM; REVIEW; SECONDARY HYPERPARATHYROIDISM; SOFT TISSUE CALCIFICATION; SYMPTOMATOLOGY;

HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CALCIUM-SENSING; RECEPTORS, CELL SURFACE;

EID: 0043136369     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.8.1413     Document Type: Review

References (44)

1. BILEZIKIAN JP, POTTS JT Jr, FULEIHAN GEL H et al.: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J. Clin. Endocrinol. Metab. (2002) 87:5353-5361.
2. SLATOPOLSKY E, BROWN A, DUSSO A: Pathogenesis of secondary hyperparathyroidism. Kidney Int. Suppl. (1999) 73:S14-S19.
3. LLACH F: Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences. Kidney Int. Suppl. (1999) 73:S31-S37.
4. KIDNEY DISEASE OUTCOME QUALITY INITIATIVE: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. (2002) 39:S1-246.
5. SLATOPOLSKY E, DUSSO A, BROWN AJ: The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am. J. Med. Sci. (1999) 317:370-376.
6. DRUEKE TB,ECKARDT KU: Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol. Dial. Transplant. (2002) 17(Suppl. 5):28-31.
7. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31:607-617.
8. GANESH SK, STACK AG, LEVIN NW, HULBERT-SHEARON T, PORT FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. (2001) 12:2131-2138.
9. MALLUCHE HH, MAWAD H, KOSZEWSKI NJ: Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int. (2002) 62:367-374.
10. LOCATELLI F, CANNATA-ANDIA JB, DRUEKE TB et al.: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol. Dial. Transplant. (2002) 17:723-731.
11. FRAZAO JM, MARTINS P, COBURN JW: The calcimimetic agents: perspectives for treatment. Kidney Int. Suppl. (2002):149-154.
12. WADA M, FURUYA Y, SAKIYAMA J et al.: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J. Clin. Invest. (1997) 100:2977-2983.
13. WADA M, NAGANO N, FURUYA Y et al.: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. (2000) 57:50-58.
14. ADAMI S, MARCOCCI C, GATTI D: Epidemiology of primary hyperparathyroidism in Europe. J. Bone Miner. Res. (2002) 17(Suppl. 2):N18-N23.
15. CORESH J, ASTOR BC, GREENE T, EKNOYAN G, LEVEY AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. (2003) 41:1-12.
16. Medication Use Among Dialysis Patients In The Dialysis Morbidity And Mortality Study (Chapter 4). USRDS 1998 Annual Report. (1998).
17. 2+ by parathyroid and kidney cells. Eur. J. Endocrinol. (1995) 132:523-531.
18. BROWN EM, GAMBA G, RICCARDI D et al.: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature (1993) 366:575-580.
19. RICCARDI D, LEE WS, LEE K et al.: Localization of the extracellular Ca(2+)-sensing receptor and PTH/PTHrP receptor in rat kidney. Am. J. Physiol. (1996) 271:F951-F956.
20. GOODMAN WG: Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol. Dial. Transplant. (2002) 17:204-207.
21. SANDS JM, NARUSE M, BAUM M et al.: Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J Clin. Invest. (1997) 99:1399-1405.
22. POLLAK MR, BROWN EM, CHOU YH et al.: Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell (1993) 75:1297-1303.
23. OLGAARD K, LEWIN E: Prevention of uremic bone disease using calcimimetic compounds. Ann. Rev. Med. (2001) 52:203-220.
24. LEWIN E, GARFIA B, RECIO FL, RODRIGUEZ M, OLGAARD K: Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. J. Am. Soc. Nephrol. (2002) 13:2110-2116.
25. HAMMERLAND LG, GARRETT JE, HUNG BC, LEVINTHAL C, NEMETH EF: Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol. Pharmacol. (1998) 53:1083-1088.
26. WANG B, OSBORN K, BLAISDELL P et al.: Pharmacokinetics (PK) of calcimimetic AMG 073 in secondary hyperparathyroidism (SHPT). Clin. Pharmacol. Ther. (2001) 69:91.
27. PEACOCK M, SHOBACK DM, GRETH WE et al.: The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperpathyrodism (PHPT). American Society of Bone and Mineral Research 23rd Annual Meeting, Phoenix, AZ, USA (2001).
28. SHOBACK DM, FIREK AF, MIMS RB et al.: The effect of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism (PHPT). American Society of Bone and Mineral Research 23rd Annual Meeting, Phoenix, AZ, USA (2001).
29. COLLINS MT, SKARULIS MC, BILEZIKIAN JP et al.: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J. Clin. Endocrinol. Metab. (1998) 83:1083-1088.
30. PEACOCK M: Normalization of hypercalcemia with the calcimimetic AMG 073 in a patient with metastatic parathyroid cancer. American Society of Bone and Mineral Research 24th Annual Meeting. J. Bone Miner. Res. (2002):S381.
31. QUARLES LD, SPIEGEL DM, CURZI M et al.: The effects of one-year treatment with the calcimimetic AMG 073 on bone health in ESRD patients with secondary hyperparathyroidism (SHPT). J. Am. Soc. Nephrol. (2002) 13:572A-573A.
32. GOODMAN WG, HLADIK GA, TURNER SA et al.: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. (2002) 13:1017-1024.
33. DRUEKE T, CUNNINGHAM J, GOODMAN WG et al.: Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agents AMG 073. J. Am. Soc. Nephrol. (2001) 12:764A.
34. LINDBERG JS, MOE SM, GOODMAN WG et al.: The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. (2003) 63:248-254.
35. QUARLES LD, SHERRARD DJ, ADLER S et al.: The Calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J. Am. Soc. Nephrol. (2003) 14:575-583.
36. BLOCK GA, COYNE DW, GOODMAN WG et al.: The calcimimetic AMG 073: a potential novel therapy for secondary hyperparathyroidism (SHPT). J. Am. Soc. Nephrol. (2002) 13:572A.
37. MOE SM, SPRAGUE SM, ADLER S et al.: Two-year treatment with the calcimimetic AMG 073 in hemodialysis patients with secondary hyperparathyroidism (SHPT). J. Am. Soc. Nephrol. (2002) 13:572A.
38. GOODMAN WG, FRAZAO JM, GOODKIN DA et al.: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. (2000) 58:436-445.
39. GOODMAN WG, HLADIK GA, TURNER SA et al.: Multiple doses of the calcimimetic AMG 073 reduce parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism (SHPT). J. Am. Soc. Nephrol. (2000) 11:576A.
40. LINDBERG JS, MOE SM, GOODMAN WG et al.: The calcimimetic AMG 073 reduces parathyroid hormone (PTH), phosphorus (P), and calcium X phosphorus product (Ca x P) in patients with ESRD and secondary hyperparathyroidism (SHPT). J. Am. Soc. Nephrol. (2000) 11:578A.
41. QUARLES LD, SHERRARD DJ, ADLER S et al.: The calcimimetic AMG 073 reduces PTH and Ca x P in patients with secondary hyperparathyroidism (SHPT). J. Am. Soc. Nephrol. (2001) 12:771A.
42. CHIN J, MILLER SC, WADA M et al.: Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J. Am. Soc. Nephrol. (2000) 11:903-911.
43. WADA M, ISHII H, FURUYA Y et al.: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. (1998) 53:448-453.
44. ISHII H, WADA M, FURUYA Y et al.: Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone (2000) 26:175-182.